|
1
|
Prowell TM and Pazdur R: Pathological
complete response and accelerated drug approval in early breast
cancer. N Engl J Med. 366:2438–2441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kong X, Moran MS, Zhang N, Haffty B and
Yang Q: Meta-analysis confirms achieving pathological complete
response after neoadjuvant chemotherapy predicts favourable
prognosis for breast cancer patients. Eur J Cancer. 47:2084–2090.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanioka M, Sasaki M, Shimomura A,
Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T,
Ohara M, et al: Pathologic complete response after neoadjuvant
chemotherapy in HER2-overexpressing breast cancer according to
hormonal receptor status. Breast. 23:466–472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang P, Yin Y, Mo H, Zhang B, Wang X, Li
Q, Yuan P, Wang J, Zheng S, Cai R, et al: Better pathologic
complete response and relapse-free survival after carboplatin plus
paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant
chemotherapy for locally advanced triple-negative breast cancer: A
randomized phase 2 trial. Oncotarget. 7:60647–60656.
2016.PubMed/NCBI
|
|
7
|
Luangdilok S, Samarnthai N and Korphaisarn
K: Association between pathological complete response and outcome
following neoadjuvant chemotherapy in locally advanced breast
cancer patients. J Breast Cancer. 17:376–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ring AE, Smith IE, Ashley S, Fulford LG
and Lakhani SR: Oestrogen receptor status, pathological complete
response and prognosis in patients receiving neoadjuvant
chemotherapy for early breast cancer. Br J Cancer. 91:2012–2017.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kolacinska A, Morawiec J, Fendler W,
Malachowska B, Morawiec Z, Szemraj J, Pawlowska Z, Chowdhury D,
Choi YE, Kubiak R, et al: Association of microRNAs and pathologic
response to preoperative chemotherapy in triple negative breast
cancer: Preliminary report. Mol Biol Rep. 41:2851–2857. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hummel R, Hussej DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in
different tumor types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gasparini P, Cascione L, Fassan M, Lovat
F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL and
Huebner K: microRNA expression profiling identifies a four microRNA
signature as a novel diagnostic and prognostic biomarker in triple
negative breast cancers. Oncotarget. 5:1174–1184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohzawa H, Miki A, Teratani T, Shiba S,
Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, et
al: Usefulness of miRNA profiles for predicting pathological
responses to neoadjuvant chemotherapy in patients with human
epidermal growth factor receptor 2-positive breast cancer. Oncol
Lett. 13:1731–1740. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raychaudhuri M, Bronger H, Buchner T,
Kiechle M, Weichert W and Avril S: MicroRNAs miR-7 and miR-340
predict response to neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res Treat. 162:511–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pedroza-Torres A, Fernández-Retana J,
Peralta-Zaragoza O, Jacobo-Herrera N, Cantú de Leon D, Cerna-Cortés
JF, Lopez-Camarillo C and Pérez-Plasencia C: A microRNA expression
signature for clinical response in locally advanced cervical
cancer. Gynecol Oncol. 142:557–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petrillo M, Zannoni GF, Beltrame L,
Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L,
Vizzielli G, Scambia G, et al: Identification of high-grade serous
ovarian cancer miRNA species associated with survival and drug
response in patients receiving neoadjuvant chemotherapy: A
retrospective longitudinal analysis using matched tumor biopsies.
Ann Oncol. 27:625–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
García-Vazquez R, Ruiz-García E, Meneses
García A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda
A, Maldonado-Martínez H, González-Barrios JA, Campos-Parra AD,
Rodríguez Cuevas S, et al: A microRNA signature associated with
pathological complete response to novel neoadjuvant therapy regimen
in triple-negative breast cancer. Tumour Biol.
39:10104283177028992017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Syed V: TGF-β signaling in cancer. J Cell
Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hiyoshi Y, Akiyoshi T, Inoue R, Murofushi
K, Yamamoto N, Fukunaga Y, Ueno M, Baba H, Mori S and Yamaguchi T:
Serum miR-143 levels predict the pathological response to
neoadjuvant chemoradiotherapy in patients with locally advanced
rectal cancer. Oncotarget. 8:79201–79211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Kang X, Xia X, Wo L, Gu X, Hu Y,
Xie X, Chang H, Lou L and Shen X: miR-145 suppresses breast cancer
cell migration by targeting FSCN-1 and inhibiting
epithelial-mesenchymal transition. Am J Transl Res. 8:3106–3114.
2016.PubMed/NCBI
|
|
24
|
Gao M, Miao L, Liu M, Li C, Yu C, Yan H,
Yin Y, Wang Y, Qi X and Ren J: miR-145 sensitizes breast cancer to
doxorubicin by targeting multidrug resistance-associated protein-1.
Oncotarget. 7:59714–59726. 2016.PubMed/NCBI
|
|
25
|
Zheng M, Wu Z, Wu A, Huang Z, He N and Xie
X: MiR-145 promotes TNF-α-induced apoptosis by facilitating the
formation of RIP1-FADD caspase-8 complex in triple-negative breast
cancer. Tumour Biol. 37:8599–8607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan X, Chen X, Liang H, Deng T, Chen W,
Zhang S, Liu M, Gao X, Liu Y, Zhao C, et al: miR-143 and miR-145
synergistically regulate ERBB3 to suppress cell proliferation and
invasion in breast cancer. Mol Cancer. 13:2202014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Götte M, Mohr C, Koo CY, Stock C, Vaske
AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, et al:
miR-145-dependent targeting of junctional adhesion molecule A and
modulation of fascin expression are associated with reduced breast
cancer cell motility and invasiveness. Oncogene. 29:6569–6580.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng
L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth
through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
|
|
29
|
Saunus JM, Smart CE, Kutasovic JR,
Johnston RL, Kalita-de Croft P, Miranda M, Rozali EN, Vargas AC,
Reid LE, Lorsy E, et al: Multidimensional phenotyping of breast
cancer cell lines to guide preclinical research. Breast Cancer Res
Treat. 167:289–301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding Y, Zhang C, Zhang J, Zhang N, Li T,
Fang J, Zhang Y, Zuo F, Tao Z, Tang S, et al: miR-145 inhibits
proliferation and migration of breast cancer cells by directly or
indirectly regulating TGF-β1 expression. Int J Oncol. 50:1701–1710.
2017. View Article : Google Scholar : PubMed/NCBI
|
